Chris Taitague

• How can acquired biotechs and their new parent company protect innovation, engagement and critical talent through the highest risk period of integration?
• Learn how Roche’s M&A team manages the full arc of a deal, from due diligence through integration, with a particular focus on employee experience as the factor that determines whether an acquisition ultimately succeeds
• Discover the practical tools used to keep teams engaged and productive through cultural and structural change, including how Roche balances global consistency with the realities of function and site level culture

This interactive Q&A explores how to protect engagement and critical talent through M&A integration and function wind-downs alike.

• Managing a deal’s full arc, from due diligence through post-merger integration, with employee experience as the deciding factor
• Knowing when to shift resources from one function to another as priorities change
• Using full transparency about an organization’s likely trajectory to retain talent through uncertainty